Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation
Launched by NATIONAL CANCER INSTITUTE, SLOVAKIA · Dec 30, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the role of the microbiome, which is the community of microorganisms living in our bodies, in cancer patients undergoing high-dose chemotherapy and stem cell transplantation or CAR-T cell therapy. Researchers want to understand how changes in the microbiome after these treatments might affect patients' recovery, especially regarding complications like infections or disease recurrence. The goal is to see if the microbiome can provide important clues about how well patients are responding to treatment and their overall immune recovery.
To participate in this study, you need to be at least 18 years old and plan to receive high-dose chemotherapy followed by stem cell transplantation or CAR-T cell therapy at the National Cancer Institute in Slovakia. If you choose to join, you'll need to sign a consent form agreeing to take part in the research. The study is currently looking for volunteers, and it might offer valuable insights that could help improve treatment outcomes for future cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • signed written informed consent
- • aged 18 years or older
- • patients planned to be treated by high-dose chemotherapy and hematopoietic cell transplantation or by CAR-T cell therapy in National Cancer Institute, Slovakia
- Exclusion Criteria:
- • - patients not-matching inclusion criteria
About National Cancer Institute, Slovakia
The National Cancer Institute of Slovakia is a leading research institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials. As a key sponsor of oncology research, the Institute collaborates with multidisciplinary teams to facilitate the development of novel therapeutic approaches and to improve patient outcomes. By leveraging state-of-the-art technology and adhering to rigorous ethical standards, the National Cancer Institute aims to enhance the understanding of cancer biology and contribute to the global fight against cancer through evidence-based practices and robust clinical evidence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bratislava, , Slovakia
Patients applied
Trial Officials
Luboš Drgoňa, Assoc. Prof.
Study Chair
National Cancer Institute, Slovakia
Michal Mego, prof.
Study Chair
National Cancer Institute, Slovakia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials